Choi EY, Park SE, Lee SC, et al. - In patients with polypoidal choroidal vasculopathy (PCV), researchers studied the long-term incidence and growth rate of chorioretinal atrophy (CRA) and determined the associated risk factors. For this investigation, they retrospectively analyzed the records of 88 patients with unilateral symptomatic PCV who received anti-vascular endothelial growth factor injections with or without photodynamic therapy (PDT). To measure the CRA area and growth rate, they used near-infrared fundus imaging and spectral domain optical coherence tomography. To estimate the CRA incidence, Kaplan-Meier survival analysis was conducted. At 5 years, the overall incidence of the CRA was 40.8%. In eyes with PCV, thin choroid can be an important risk factor for long-term development and growth of CRA. Intraretinal fluid appears to support CRA development, while subretinal fluid appears to be associated with the prevention of CRA. PDT history was significantly associated with CRA occurrence, but not with CRA's growth rate.